Citi analyst Geoff Meacham raised the firm’s price target on Pfizer (PFE) to $26 from $25 and keeps a Neutral rating on the shares. The company reported strong Q2 results but policy headwinds warrant a continued cautious stance, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE: